Print

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

https://www.facingourrisk.org/research-clinical-trials/study/209/treatment-for-metastatic-castration-sensitive-prostate-cancer-and-inherited-or-tumor-mutations-in-dna-damage-repair-genes-amplitude

Clinicaltrials.gov identifier:
NCT04497844 (https://clinicaltrials.gov/show/NCT04497844)


Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

Study Contact Information:

For additional information, please contact:
Janssen study contact at:
844-434-4210 or via email at: [email protected]

About the Study

The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L. NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

NOTE: This study is no longer enrolling patients. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.